Left ventricular hypertrophy and antihypertensive therapy.

Area of Science:

• Cardiology
• Hypertension Research
• Pharmacology

Background:

• Long-standing arterial hypertension causes left ventricular hypertrophy (LVH), increasing cardiovascular risks.
• LVH is linked to increased premature ventricular contractions and a higher risk of sudden death.
• Effective antihypertensive therapy should reduce blood pressure and reverse LVH.

Purpose of the Study:

• To evaluate the impact of different antihypertensive agents on left ventricular mass and ventricular ectopic activity.
• To determine if regression of LVH by specific drugs affects ventricular arrhythmias.
• To assess the potential of antihypertensive therapy to alter the prognosis of LVH.

Main Methods:

• Review of existing evidence on antihypertensive therapies and their effects on cardiac structure and function.
• Analysis of studies comparing the efficacy of various drug classes, including ACE inhibitors, beta-blockers, calcium antagonists, and diuretics, on LVH.
• Examination of data on ventricular ectopic activity in patients with and without LVH, and in response to different treatments.

Main Results:

• Certain antihypertensive drugs (ACE inhibitors, beta-blockers, etc.) decrease left ventricular mass, while others (diuretics, hydralazine) have minimal or detrimental effects.
• Drug-induced regression of left ventricular mass significantly suppresses ventricular ectopic activity (by 85%).
• Diuretic therapy does not alter left ventricular mass or ventricular ectopic activity, and may even increase them.

Conclusions:

• Antihypertensive medications vary significantly in their ability to induce left ventricular mass regression.
• Regression of LVH by specific drugs effectively suppresses ventricular ectopic activity.
• Further research is needed to ascertain if this LVH regression impacts sudden death risk and overall prognosis.